Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
68.93 USD | -0.07% | -1.26% | -7.11% |
Jun. 14 | CMS to rework quality ratings for Medicare Advantage plans | RE |
Jun. 05 | Agilon Health Names Jeff Schwaneke CFO | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.26 for the 2024 fiscal year.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is not the most generous with respect to shareholders' compensation.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.11% | 36.78B | B- | ||
-5.57% | 458B | B- | ||
+13.41% | 124B | A- | ||
+11.30% | 94.68B | B- | ||
-21.60% | 43.25B | A- | ||
-15.02% | 17.99B | B- | ||
-27.43% | 2.57B | C+ | ||
-3.37% | 1.59B | B- | ||
+14.48% | 541M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CNC Stock
- Ratings Centene Corporation